Evidence map›Paper›PMID 35160138›Full record

ArticleJournal of clinical medicine2022

Effectiveness of Lifestyle Modification vs. Therapeutic, Preventative Strategies for Reducing Cardiovascular Risk in Primary Prevention-A Cohort Study.

Małgorzata Chlabicz, Jacek Jamiołkowski, Wojciech Łaguna, Marlena Dubatówka, Paweł Sowa, Magda Łapińska, Anna Szpakowicz, Natalia Zieleniewska, Magdalena Zalewska, Andrzej Raczkowski and 1 more

Abstract read
In one paragraph

Article in Journal of clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Małgorzata ChlabiczDepartment of Population Medicine and Lifestyle Diseases Prevention, Medical University of Białystok, 15-259 Białystok, Poland.ORCID 0000-0002-5113-5672
Jacek JamiołkowskiDepartment of Population Medicine and Lifestyle Diseases Prevention, Medical University of Białystok, 15-259 Białystok, Poland.
Wojciech ŁagunaFaculty of Computer Science, Bialystok University of Technology, 15-259 Białystok, Poland.
Marlena DubatówkaDepartment of Population Medicine and Lifestyle Diseases Prevention, Medical University of Białystok, 15-259 Białystok, Poland.ORCID 0000-0001-5977-0745
Paweł SowaDepartment of Population Medicine and Lifestyle Diseases Prevention, Medical University of Białystok, 15-259 Białystok, Poland.ORCID 0000-0002-8357-5816
Magda ŁapińskaDepartment of Population Medicine and Lifestyle Diseases Prevention, Medical University of Białystok, 15-259 Białystok, Poland.
Anna SzpakowiczDepartment of Cardiology, Medical University of Białystok, 15-259 Białystok, Poland.
Natalia ZieleniewskaDepartment of Population Medicine and Lifestyle Diseases Prevention, Medical University of Białystok, 15-259 Białystok, Poland.
Magdalena ZalewskaDepartment of Population Medicine and Lifestyle Diseases Prevention, Medical University of Białystok, 15-259 Białystok, Poland.ORCID 0000-0001-6470-1787
Andrzej RaczkowskiDepartment of Population Medicine and Lifestyle Diseases Prevention, Medical University of Białystok, 15-259 Białystok, Poland.
Karol A KamińskiDepartment of Population Medicine and Lifestyle Diseases Prevention, Medical University of Białystok, 15-259 Białystok, Poland.ORCID 0000-0002-9465-2581

Funding

the Medical University of Bialystok for the Bialystok PLUS study, Poland SUB/1/00/19/001/1201the Municipal Office in Bialystok, Poland W/UB/DSP/1640/UMBIAŁYSTOK/2017
6 · The paper itself

Abstract

backgroundCardiovascular diseases (CVD) are still the leading cause of death in developed countries. The aim of this study was to calculate the potential for CV risk reduction when using three different prevention strategies to evaluate the effect of primary prevention.

methodsA total of 931 individuals aged 20-79 years old from the Bialystok PLUS Study were analyzed. The study population was divided into CV risk classes. The Systematic Coronary Risk Estimation (SCORE), Framingham Risk Score (FRS), and LIFE-CVD were used to assess CV risk. The optimal prevention strategy assumed the attainment of therapeutic goals according to the European guidelines. The moderate strategy assumed therapeutic goals in participants with increased risk factors: a reduction in systolic blood pressure by 10 mmHg when it was above 140 mmHg, a reduction in total cholesterol by 25% when it was above 190 mg/dL, and a reduction in body mass index below 30. The minimal prevention strategy assumed that CV risk would be lowered by lifestyle modifications. The greatest CV risk reduction was achieved in the optimal model and then in the minimal model, and the lowest risk reduction was achieved in the moderate model, e.g., using the optimal model of prevention (Model 1). In the total population, we achieved a reduction of -1.74% in the 10-year risk of CVD death (SCORE) in relation to the baseline model, a -0.85% reduction when using the moderate prevention model (Model 2), and a -1.11% reduction when using the minimal prevention model (Model 3). However, in the low CV risk class, the best model was the minimal one (risk reduction of -0.72%), which showed even better results than the optimal one (reduction of -0.69%) using the FRS.

conclusionA strategy based on lifestyle modifications in a population without established CVD could be more effective than the moderate strategy used in the present study. Moreover, applying a minimal strategy to the low CV risk class population may even be beneficial for an optimal model.

Indexed as

cardiovascular risklifestyle modificationpopulation studies

Identifiers

PMID35160138
PMCPMC8836845

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.